New shot slashes hidden heart risk in landmark trial

NCT ID NCT04270760

First seen Apr 07, 2026 · Last updated May 14, 2026 · Updated 6 times

Summary

This study tested a new drug called olpasiran in 281 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease. Participants received either the drug or a placebo as a shot. The main goal was to see if olpasiran could safely lower Lp(a) levels over several months. The trial has completed, and results show it effectively reduced this risk factor.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aarhus Universitetshospital

    Aarhus N, 8200, Denmark

  • Academisch Medisch Centrum

    Amsterdam, 1105 AZ, Netherlands

  • Asahi General Hospital

    Asahi-shi, Chiba, 289-2511, Japan

  • Asahikawa City Hospital

    Asahikawa-shi, Hokkaido, 070-8610, Japan

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Clinique des Maladies Lipidiques de Quebec Incorporated

    Québec, Quebec, G1V 4W2, Canada

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Core Research Group Pty Ltd

    Milton, Queensland, 4064, Australia

  • Crossroads Clinical Research Inc

    Mooresville, North Carolina, 28117, United States

  • Dr Heart Pty Ltd

    Woolloongabba, 4102, Australia

  • Ecogene-21

    Chicoutimi, Quebec, G7H 7K9, Canada

  • Excel Medical Clinical Trials

    Boca Raton, Florida, 33434, United States

  • Haga Ziekenhuis

    The Hague, 2545 AA, Netherlands

  • Herlev Gentofte Hospital

    Herlev, 2730, Denmark

  • Johns Hopkins

    Baltimore, Maryland, 21287, United States

  • Kanazawa Medical University Hospital

    Kahoku-gun, Ishikawa-ken, 920-0293, Japan

  • LMC Clinical Research Incorporated

    Brampton, Ontario, L6S 0C6, Canada

  • LMC Clinical Research Incorporated Thornhill

    Concord, Ontario, L4K 4M2, Canada

  • Linear Clinical Research Limited

    Nedlands, Western Australia, 6009, Australia

  • Monash Medical Centre

    Clayton, Victoria, 3168, Australia

  • Mount Sinai Hospital

    New York, New York, 10029, United States

  • New York University

    New York, New York, 10016, United States

  • Piedmont Healthcare

    Atlanta, Georgia, 30309, United States

  • Protenium Clinical Research

    Hurst, Texas, 76054, United States

  • Regionshospitalet Viborg

    Viborg, 8800, Denmark

  • Research Institute of McGill University Health Center - Glen Site

    Montreal, Quebec, H4A 3J1, Canada

  • Rijnstate Ziekenhuis

    Arnhem, 6815 AD, Netherlands

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, 2050, Australia

  • Saitama Medical University Hospital

    Iruma-gun, Saitama, 350-0495, Japan

  • The Jikei University Kashiwa Hospital

    Kashiwa-shi, Chiba, 277-8567, Japan

  • Thjonustumidstod Rannsoknaverkefna

    Kopavogur, 201, Iceland

  • Universitair Medisch Centrum Utrecht

    Utrecht, 3584 CX, Netherlands

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • VieCuri Medisch Centrum

    Venlo, 5912 BL, Netherlands

  • Westside Medical Associates of Los Angeles

    Beverly Hills, California, 90211, United States

Conditions

Explore the condition pages connected to this study.